The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

NEW YORK – Autoimmune testing firm Exagen on Tuesday announced its Q3 revenues declined 7 percent year over year. For the three months ended Sept. 30, the firm posted revenues of $12.5 million, down ...

Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.

The certification is for products used in hematology instruments manufactured globally, including instruments from Abbott, Beckman Coulter, and Siemens Healthineers.

The research team looked at cell-free DNA fragmentation profiles across the genome combined with measurements of two key biomarkers to detect ovarian cancer.

The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

NEW YORK – Adaptive Biotechnologies on Thursday reported a 22 percent increase in Q3 revenues driven by an increase in minimal residual disease testing.

The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.

The firm had received notice last year that it was out of compliance with a requirement to maintain a minimum $15 million market value of publicly held shares.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

The firm reported that its adjusted diagnostics revenues rose less than 1 percent, excluding the COVID-19 rapid antigen testing business that the firm exited last year.

NEW YORK – AI diagnostics firm Tempus said on Tuesday that it has inked a deal with Roche's Flatiron Health that will allow healthcare providers to order Tempus' genomic cancer tests through ...